A 13-week trial has found that a hybrid closed-loop automated insulin delivery system improved time-in-range for blood glucose compared with standard care for children with Type 1 diabetes.
Type 1 diabetes treatment is particularly challenging in children younger than 6 because of their small insulin dosing requirements and unpredictable eating and activity habits.
In this study of 102 children with Type 1 diabetes aged at least 2 years but younger than 6 years, the hybrid closed-loop system (also called automated insulin delivery or artificial pancreas) used was comprised of a t:slim X2 insulin pump, a Dexcom G6 continuous glucose monitor (CGM), and Control-IQ technology system algorithm software (Tandem Diabetes Care).
In this study, time-in-range over 13 weeks was higher for those randomized to the hybrid closed-loop system compared with standard of care; the latter included either an insulin pump or multiple daily injections plus a separate Dexcom G6 CGM. The hybrid closed-loop system added an average of about 3 hours in ideal blood glucose range over the 13 weeks, compared to no change with standard care.